Immuno Group's sales up 2% in 1994:
This article was originally published in Clinica
Executive Summary
The Immuno Group, which has diagnostic and PCR technology interests, reported sales of SwFr 636.3 million ($552 million) in 1994, up 2% over the previous year, and net earnings of SwFr 35 million, a rise of 9%.
You may also be interested in...
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
Executives On The Move: Changes At The Top At Viatris And Clinuvel Among This Week's Announcements
Recent moves in the industry include C-suite shuffle at Brainstorm Cell Therapeutics and new CFOs at Faron Pharmaceuticals and Foghorn Therapeutics, among others.